cisplatin,erdafitinib,cetrelimab,enfortumab,Pembrolizumab,carboplatin,gemcitabine,Atezolizumab
janssen,Astellas,Merck,Seagen,Roche
['biomarker', 'cisplatin']
fantastic talk by on the therapeutic landscape of muc.
lots of variation in clinical trials for first line cisplatin-ineligible muc. different eligibility criteria, biomarkers, median follow-up times etc. #asco2023 
@UroOnc fellow @UCLAUrology | @CleClinicUro-trained urologist | @DukeMedSchool @UCLA alumna | Semi-retired dancer | fitness & fashion aficionado | Views=my own